{"id":"dalbavancin-via-intravenous-administration","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vulvovaginal mycotic infection"}]},"_chembl":{"chemblId":"CHEMBL3301669","moleculeType":"Protein","molecularWeight":"1816.72"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dalbavancin binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors in bacterial cell walls, preventing cross-linking and disrupting cell wall integrity. This leads to bacterial cell lysis and death. It has enhanced activity against gram-positive bacteria compared to earlier glycopeptides due to its improved tissue penetration and longer half-life.","oneSentence":"Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:04.606Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive organisms"},{"name":"Staphylococcus aureus bacteremia including endocarditis"}]},"trialDetails":[{"nctId":"NCT02940730","phase":"PHASE4","title":"Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-05-01","conditions":"Infectious Peritonitis","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dalbavancin via Intravenous Administration","genericName":"Dalbavancin via Intravenous Administration","companyName":"University of Colorado, Denver","companyId":"university-of-colorado-denver","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. Used for Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive organisms, Staphylococcus aureus bacteremia including endocarditis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}